Travere Therapeutics マネジメント
マネジメント 基準チェック /24
Travere Therapeuticsの CEO はEric Dubeで、 Jan2019年に任命され、 の在任期間は 5.83年です。 の年間総報酬は$ 7.57Mで、 10.5%給与と89.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.14%を直接所有しており、その価値は$ 2.10M 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と7.6年です。
主要情報
Eric Dube
最高経営責任者
US$7.6m
報酬総額
| CEO給与比率 | 10.5% |
| CEO在任期間 | 5.8yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 4.1yrs |
| 取締役会の平均在任期間 | 7.6yrs |
経営陣の近況
Recent updates
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry
Oct 31
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Oct 07Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Sep 30Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sep 10Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Aug 30Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$349m |
| Jun 30 2024 | n/a | n/a | -US$383m |
| Mar 31 2024 | n/a | n/a | -US$416m |
| Dec 31 2023 | US$8m | US$796k | -US$376m |
| Sep 30 2023 | n/a | n/a | -US$373m |
| Jun 30 2023 | n/a | n/a | -US$368m |
| Mar 31 2023 | n/a | n/a | -US$352m |
| Dec 31 2022 | US$6m | US$747k | -US$331m |
| Sep 30 2022 | n/a | n/a | -US$297m |
| Jun 30 2022 | n/a | n/a | -US$249m |
| Mar 31 2022 | n/a | n/a | -US$202m |
| Dec 31 2021 | US$6m | US$708k | -US$217m |
| Sep 30 2021 | n/a | n/a | -US$250m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$224m |
| Dec 31 2020 | US$5m | US$661k | -US$169m |
| Sep 30 2020 | n/a | n/a | -US$78m |
| Jun 30 2020 | n/a | n/a | -US$92m |
| Mar 31 2020 | n/a | n/a | -US$105m |
| Dec 31 2019 | US$10m | US$618k | -US$146m |
報酬と市場: Ericの 総報酬 ($USD 7.57M ) は、 US市場 ($USD 5.38M ) の同規模の企業の平均を上回っています。
報酬と収益: Ericの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Eric Dube (51 yo)
5.8yrs
在職期間
US$7,574,959
報酬
Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.14% $ 2.1m | |
| Chief Financial Officer | 2.3yrs | US$1.97m | 0.086% $ 1.3m | |
| Senior VP | 7.8yrs | US$2.02m | 0.090% $ 1.4m | |
| Senior VP and Head of Research & Development | 7.8yrs | US$2.05m | 0.041% $ 619.0k | |
| Chief Commercial Officer | 5.1yrs | US$2.00m | 0.068% $ 1.0m | |
| SVP, Corporate Controller & Chief Accounting Officer | 3.2yrs | データなし | 0.060% $ 904.6k | |
| Vice President of Corporate Communications & Investor Relations | no data | データなし | データなし | |
| Senior Vice President of Human Resources | no data | データなし | データなし | |
| Chief Business Officer | less than a year | データなし | データなし | |
| Chief Medical Officer | 2.8yrs | US$2.87m | 0.071% $ 1.1m | |
| Senior Vice President of Public Affairs | no data | データなし | データなし |
4.1yrs
平均在職期間
52yo
平均年齢
経験豊富な経営陣: TVTXの経営陣は 経験豊富 であると考えられます ( 4.1年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.14% $ 2.1m | |
| Independent Director | 7.7yrs | US$372.98k | 0.033% $ 502.2k | |
| Independent Chairman of the Board | 10.1yrs | US$392.98k | 0.059% $ 886.9k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 4.6yrs | US$372.36k | 0.026% $ 386.9k | |
| Independent Director | 8.4yrs | US$376.73k | 0.036% $ 539.1k | |
| Independent Director | 3.2yrs | US$365.48k | 0.022% $ 334.8k | |
| Independent Director | 9.7yrs | US$385.48k | 0.056% $ 852.1k | |
| Independent Director | 7.6yrs | US$367.98k | 0.033% $ 502.2k | |
| Independent Director | 10.1yrs | US$379.98k | 0.093% $ 1.4m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.5yrs | US$369.86k | 0.027% $ 408.7k |
7.6yrs
平均在職期間
60yo
平均年齢
経験豊富なボード: TVTXの 取締役会 は 経験豊富 であると考えられます ( 7.6年の平均在任期間)。